TABLE 4.
Male-to-Female Transgender Persons Hormone Use, by Current Health Care Provider: New York City, 2007
| Total Responses (n = 71), No. (%) | General Practitioner and Mental Health Provider (n = 43), No. (%) | General Practitioner or Mental Health Provider (n = 18), No. (%) | No Health Care Provider (n = 10), No. (%) | P | |
| Mode of hormone administration | |||||
| Pill | 59 (83.1) | 36 (83.7) | 17 (94.4) | 6 (60.0) | .071 |
| Injectable | 47 (66.2) | 27 (62.8) | 11 (61.1) | 9 (90.0) | .424 |
| Gel or cream | 5 (7.0) | 4 (9.3) | 1 (5.6) | 0 | .418 |
| Patch | 3 (4.2) | 3 (7.0) | 0 | 0 | .260 |
| Estrogen regimens | |||||
| Delestrogena | 31 (43.7) | 20 (46.5) | 6 (33.3) | 5 (50.0) | .266 |
| Estradiol | 20 (28.2) | 14 (32.6) | 5 (27.8) | 1 (10.0) | .390 |
| Premarinb | 32 (45.1) | 20 (46.5) | 6 (33.3) | 6 (60.0) | .258 |
| Estrogen (type unknown) | 18 (25.4) | 9 (20.9) | 4 (22.2) | 5 (50.0) | .293 |
| Two or 3 estrogens | 28 (39.4) | 18 (41.9) | 3 (16.7) | 7 (70.0) | .151 |
| Progesterone | 12 (16.9) | 10 (23.3) | 2 (11.1) | 0 | .179 |
| Aldactonec (antiandrogen) | 29 (40.8) | 21 (48.8) | 8 (44.4) | 0 | .011 |
| Medical evaluation before starting hormones | 41 (57.7) | 27 (62.8) | 13 (72.2) | 1 (10.0) | .003 |
| On antipsychotics or mood stabilizers | 25 (35.2) | 22 (51.2) | 3 (16.7) | 0 | .001 |
| Poor hormone access | 21 (29.6) | 10 (23.3) | 3 (16.7) | 8 (80.0) | .001 |
| Poor hormone satisfaction | 15 (21.1) | 6 (14.0) | 4 (22.2) | 5 (50.0) | .036 |
Note. Categorical variables were analyzed with the χ2 test or the Fisher exact test (for sample sizes of n < 5 responses). The total number of responses in each category may be greater than number of participants, because many participants responded in the affirmative to more than 1 option in each category. Health care providers were identified as general practitioners or mental health providers.
a
Bristol-Myers Squibb, Princeton, NJ.
b
Wyeth Pharmaceuticals, Philadelphia, PA.
c
Pfizer, New York, NY.